Search

Corvus Pharmaceuticals Inc

Geschlossen

13.14 1.94

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.85

Max

12.98

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+128.51% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

86M

1.2B

Vorheriger Eröffnungskurs

11.2

Vorheriger Schlusskurs

13.14

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Sept. 2026, 23:51 UTC

Brazil's Business Confidence Index (ICEI) for September 2026 set to release on September 14, with cautious optimism amid persistent pessimism and geopolitical challenges.

13. Sept. 2026, 23:41 UTC

GBP/AUD shows notable strength in after-market trading, reaching a cumulative return peak of 0.17% since Friday's close, with no specific news identified.

13. Sept. 2026, 23:41 UTC

Correlated Moves

EUR/AUD is higher in after-market trading, diverging from the lower Nasdaq 100 Index amid heightened Fed interest rate hike expectations following a strong consumer price index report.

13. Sept. 2026, 23:31 UTC

China's House Price Index YoY release on September 15, 2026, is anticipated to reveal ongoing weakness in the housing sector amid cautious optimism from recent policy measures.

13. Sept. 2026, 23:31 UTC

U.S. Building Permits Forecasted at 1.41 Million for August Amid Stable Market Sentiment Ahead of September Release

13. Sept. 2026, 23:31 UTC

Upcoming U.S. Housing Starts Data Release on September 17 Expected to Influence Economic Outlook Amidst Market Fluctuations.

13. Sept. 2026, 23:31 UTC

U.S. Housing Starts Expected to Recover Slightly to 1.32 Million Units Amid Ongoing Concerns Over High Mortgage Rates and Recent Declines

13. Sept. 2026, 23:31 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Positive Sentiment and Anticipated Growth, Forecasted at 30.0

13. Sept. 2026, 23:31 UTC

U.S. Building Permits Data Set for Release on September 17, 2026, Amid Cautious Optimism in Housing Market Sentiment

13. Sept. 2026, 23:31 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Cautious Optimism on Consumer Spending

13. Sept. 2026, 23:31 UTC

Retail Sales MoM report for August 2026 set to release on September 16, with a forecasted increase of 0.9% amid cautious consumer spending sentiment following July's unexpected decline.

13. Sept. 2026, 23:31 UTC

U.S. Import Prices MoM data for August 2026 set to release on September 16, with a modest increase of 0.2% expected amid inflation concerns and potential Fed interest rate adjustments.

13. Sept. 2026, 23:31 UTC

U.S. Export Prices MoM Release on September 16 Expected to Impact Monetary Policy Amidst Recent Price Decline and Mixed Market Sentiment

13. Sept. 2026, 23:21 UTC

Macro News
News

Bitcoin is lower as U.S.-China tensions rise and crude oil prices fall. Regulatory optimism around the Bitcoin and Crypto Clarity Act fails to boost sentiment.

13. Sept. 2026, 23:11 UTC

EUR/NZD is trading lower during after-market hours, settling at -0.11%. The currency pair remains above its 20-day moving average.

13. Sept. 2026, 23:01 UTC

EUR/JPY trades higher in after-market hours, recovering from earlier lows amid expectations for a Federal Reserve interest rate hike on September 16.

13. Sept. 2026, 23:01 UTC

Correlated Moves

The AUD/USD is lower during after-market hours, reflecting declines in the Nasdaq 100 Index and influenced by recent consumer price index data.

13. Sept. 2026, 23:01 UTC

Macro News
Correlated Moves

Geopolitical tensions with China and domestic electricity concerns contribute to a decline in the Dow Jones Index, which has reached a session low below its 20-day moving average.

13. Sept. 2026, 23:01 UTC

Macro News
Correlated Moves

U.S.-China tensions rise over arms deals with Taiwan, impacting market sentiment. The S&P 500 Index is trading lower today, reflecting broader market weakness.

13. Sept. 2026, 23:01 UTC

Macro News

Geopolitical tensions are driving WTI prices higher as concerns about U.S.-China relations and Iranian pressures on Saudi Arabia impact global oil markets.

13. Sept. 2026, 23:01 UTC

Correlated Moves

The Russell 2000 Index is lower today, continuing a downward trend amid broader market sentiment influenced by rising core CPI data and Fed rate hike expectations.

13. Sept. 2026, 23:01 UTC

Correlated Moves

Platinum is trading lower, influenced by a decline in silver prices amid rising consumer inflation and expectations for a Federal Reserve interest rate hike.

13. Sept. 2026, 23:01 UTC

EUR/SEK is trading lower during after-market hours, reflecting a slight decline since Friday's close. The asset remains near its one-month range high.

13. Sept. 2026, 23:01 UTC

Correlated Moves

Silver prices are lower, influenced by gold's decline and inflation data. The asset remains below its 20-day moving average amid market pressures.

13. Sept. 2026, 23:01 UTC

The Nasdaq 100 Index is lower amid ongoing market weakness, following a consumer price index report that exceeded expectations and heightened rate hike speculation.

13. Sept. 2026, 23:01 UTC

Natural Gas is trading higher, continuing gains from Friday's close. Prices reached their highest point during the session, with no specific news identified.

13. Sept. 2026, 23:01 UTC

EUR/CZK is trading lower in after-market hours, reflecting a modest decline since Friday's close amid solidified market expectations for a Federal Reserve interest rate hike.

13. Sept. 2026, 23:01 UTC

Macro News
Correlated Moves

Gold prices are lower as market expectations grow for a Federal Reserve interest rate hike. Goldman Sachs anticipates a 25 basis-point increase at the FOMC meeting.

13. Sept. 2026, 23:01 UTC

Ethereum is trading lower, continuing a downward trend since Saturday's close. The asset reached a session low earlier today.

13. Sept. 2026, 22:51 UTC

Canada's Housing Starts Data Release on September 16 Expected to Show Continued Weakness Amid Economic Pressures

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

128.51% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  128.51%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat